Opna Bio develops
drugs targeting the
Hallmarks of Cancer

OPN-7486

Dual Inhibitor
of CSF1R and TRK

Tumor promoting
inflammation

OPN-TEAD

TEAD
Inhibitor

Evading growth
supressors

OPN-2853

BET
Inhibitor

Nonmutational epigenetic
reprogramming

OPN-FMRP

FMRP
Inhibitor

Avoiding immune
destruction

OUR PIPELINE

In addition to its discovery-stage FMRP program, Opna’s lead clinical compound, OPN-2853, a bromo and extra terminal (BET) domain inhibitor, is currently in a Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The company also expects to initiate a Phase 2 study with OPN-7486, a colony stimulating factor 1 (CSF1) receptor inhibitor, in patients with histiocytosis, a white blood cell disorder, in the first half of 2023.

EXPLORE
Hanahan et al, November 2022

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Upregulation of the neuronal fragile X mental retardation protein in cancer cells suppresses proinflammatory signals to circumvent tumor immunity

Read More